Phase 1/2 Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Participants With Advanced Solid Tumors
Phase of Trial: Phase I/II
Latest Information Update: 01 Nov 2019
Price : $35 *
At a glance
- Drugs Nivolumab (Primary) ; ONO 4578 (Primary)
- Indications Bladder cancer; Colorectal cancer; Head and neck cancer; Malignant melanoma; Renal cell carcinoma; Solid tumours; Squamous cell cancer
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 17 Jul 2019 Planned number of patients changed from 280 to 308.
- 17 Jul 2019 Planned End Date changed from 31 Mar 2023 to 12 Sep 2023.
- 17 Jul 2019 Planned primary completion date changed from 31 Mar 2023 to 12 Sep 2023.